P3781
Blinatumomab Expanded T-cells (BET) in Indolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaLenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin LymphomaBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic LeukemiaPembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or LymphomaBlinatumomab and Pembrolizumab for Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia With High Marrow LymphoblastsClinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaClinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic LeukemiaTreatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017Blinatumomab in High-risk B-cell Precursor Acute Lymphoblastic LeukemiaTreatment of Older Patients With B-precursor ALL With Sequential Dose Reduced Chemotherapy and BlinatumomabBlinatumomab Added to Prephase and Consolidation Therapy in Precursor B-acute Lymphoblastic Leukemia in Adults.Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaPembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic LeukemiaA Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's LymphomaBlinatumomab in Combination With Chemotherapy in Treating Patients With or Without Down Syndrome and Newly Diagnosed, Standard Risk B-Lymphoblastic Leukemia or Localized B-Lymphoblastic LymphomaBlinatumomab Plus HLA-Mismatched Cellular Therapy for Relapsed/Refractory CD19+ ALLEfficacy and Toxicity of Blinatumomab in the French ATU for Adult BCP-ALL R/R, or With MRD+ (FRENCH-CYTO)Blinatumomab and Ponatinib in Patients With Philadelphia Chromosome (Ph)-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin LymphomaBlinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic LeukemiaPediatric-type Therapy With Pre-transplant Blinatumomab for HR Patients - Phase II Study
P4844
Q61727948-CF4F4B7E-838B-473C-B51F-6B195AE04D5FQ61862236-5BD08550-BB30-4C01-8CBD-B34DC144FC3FQ61864749-99D96608-EED1-4CD8-BF7C-532571ED9F6AQ61907289-F69BFC37-949A-4D38-8ABD-247426772E25Q61909307-82E94DED-B8C6-406F-AAA5-E001D170365DQ61955521-D747D270-5635-4871-B780-22CAA66EB023Q61956389-42DDB6C6-9BB4-42BD-8369-A235FD93CD0EQ61969291-DEC6E0FC-6501-4352-B1F4-F05457DE0A02Q62026003-70097E9D-8847-495B-8DDC-FE2D13740CA1Q62042209-E37D41BF-8F44-4537-91B9-B9DA501C3BEFQ62811474-8C29A1AC-DCA5-423A-B432-E7F5DDDD6C8BQ62811927-A25E80F0-42F4-4014-825E-6C70EDD9DEEDQ62813599-35138DED-CF6D-445E-BCF0-7B192745324BQ62817251-BF4E0012-6D1E-441A-84B0-CDB9C303D762Q63228920-6A5EBB18-FE30-43CB-AF75-0819944960EEQ63535060-B4DC6C14-5A95-41C6-9782-C93F46263F9AQ63574324-C33AA5FB-35C7-4C5E-9B95-350190A904C6Q63577219-EB687A82-A658-467E-8DD2-04E949DCE989Q63578202-97966410-ABBB-491A-8A64-52980A31E35DQ63595293-3644FA05-E200-402D-9701-19BF85D5BAAFQ63595469-55C00F28-FEA7-4237-B66C-00D5752843C2Q63811979-5B76DC9C-58C0-4647-AF29-66D34ADEF884Q63813285-5D506498-1AA1-4E2B-995B-1E28CE3DCE3DQ89435783-B0484474-1A17-4731-91A1-AD32068D9249Q90693704-01EC8234-E70E-4F74-A876-33112B317C55
P4844
description
Protein
@de
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
component quimic
@oc
name
Blinatumomab
@de
Blinatumomab
@en
Blinatumomab
@es
Blinatumomab
@it
Blinatumomab
@nl
blinatumomab
@fr
בלינטומומב
@he
بليناتوموماب
@ar
type
label
Blinatumomab
@de
Blinatumomab
@en
Blinatumomab
@es
Blinatumomab
@it
Blinatumomab
@nl
blinatumomab
@fr
בלינטומומב
@he
بليناتوموماب
@ar
prefLabel
Blinatumomab
@de
Blinatumomab
@en
Blinatumomab
@es
Blinatumomab
@it
Blinatumomab
@nl
blinatumomab
@fr
בלינטומומב
@he
بليناتوموماب
@ar
P31
P486
P6366
P646
P665
P2115
N0000191284
P231
853426-35-4
P267
P2868
P3345
P3780
P486
P6366
2778020697
P646
/m/04gm0f3
P652
4FR53SIF3A
P665
P7830
Blinatumomab